Mice treated with MK2206 plus dexamethasone showed a significant reduction of tumor burden, while tumor growth was similar in the other study, suggesting that AKT modulation may control glucocorticoid resistant cells in T-ALL [31]. Here, AKT1 is linked to acute lymphoblastic leukemia.